As many readers will remember, Prostvac is an active immunotherapeutic vaccine that — some years ago — had shown promising results in a randomized Phase II clinical trial.
A multinational, three-arm, Phase III, double-blind, randomized, placebo-controlled clinical trial that enrolled > 1,200 patients with metastatic, castration-resistant prostate cancer (mCRPC) was initiated in late 2011 and had been fully enrolled by 2015.
Unfortunately, in September 2017, it became apparent that, although Prostvac appeared to be safe as a therapeutic agent, it was showing no signs of effectiveness in the treatment of men with mCRPC in this large clinical trial.
The full report on the results of this trial as of the time the study was terminated have just been reported by Gulley et al. in the Journal of Clinical Oncology, and the full text of this paper is freely available on line.
It should be noted, however, that seven other trials of Prostvac are ongoing (see here) and still recruiting patients with a variety of different stages of prostate cancer.
Filed under: Uncategorized | Tagged: clinical, Prostvac, trial |
THE "NEW" PROSTATE CANCER INFOLINK 
Thus, still in limbo unless combination medications to include Prostvac are determined beneficial in current, ongoing, trials. At least Prostvac is going down fighting!